循环肿瘤DNA检测在人乳头瘤病毒相关性宫颈癌中的应用与展望

doi:10.3969/j.issn.1006-5725.2024.02.001

Abstract

Abstract:

Circulating tumor DNA （ctDNA） is a kind of cell-free DNA derived from tumors， which carries comprehensive tumor genetic information； Recent studies have found that ctDNA detection can play a role in the early diagnosis， targeted therapy， and prediction of recurrence in tumors. Human papillomavirus （HPV）-associated gynecological malignancies include most cervical cancer， some vulvar cancer， and vaginal cancer. High-risk HPV long-term infection and integration with cell genome are important causes of these cancers. Studies found that the use of ctDNA detection technology to dynamically monitor changes in HPV-ctDNA can provide valuable information for the clinical management and prognosis of these cancers. Thus， HPV-ctDNA is expected to become an biomarker for HPV- associated tumors.

Key words: HPV-ctDNA, HPV, cervical cancer, gynecologic malignancy, vulva cancer, vagina cancer

CLC Number:

R737.33

Baoni JIANG,Meiqin ZHANG,Lu YANG,Zhiyuan CHEN,Na′na HAN. Application and prospects of ctDNA detection in HPV associated cervical cancer[J]. The Journal of Practical Medicine, 2024, 40(2): 129-132.

Figures/Tables 1

References 27

1	KAZEMIFARD N， SADEGHI A， VARAMINIAN B， et al. Circulating tumor DNA applications in monitoring the treatment of metastatic colorectal cancer patients［J］. Gastroenterol Hepatol Bed Bench， 2019，12（）：S14-S21.
2	BETTEGOWDA C， SAUSEN M， LEARY R J， et al. Detection of circulating tumor DNA in early- and late-stage human malignancies［J］. Sci Transl Med， 2014，6（224）：224ra24.
3	SAAVEDRA K P， BREBI P M， ROA J C. Epigenetic alterations in preneoplastic and neoplastic lesions of the cervix［J］. Clin Epigenetics， 2012，4（1）：13. doi:10.1186/1868-7083-4-13 doi: 10.1186/1868-7083-4-13
4	中国抗癌协会妇科肿瘤专业委员会. 阴道恶性肿瘤诊断与治疗指南（2021年版）［J］.中国癌症杂志， 2021，31：546-60.
5	CAMPITELLI M， JEANNOT E， PETER M， et al. Human papillomavirus mutational insertion： specific marker of circulating tumor DNA in cervical cancer patients［J］. PLoS One， 2012，7（8）：e43393. doi:10.1371/journal.pone.0043393 doi: 10.1371/journal.pone.0043393
6	CAROW K， GöLITZ M， WOLF M， et al. Viral-Cellular DNA Junctions as Molecular Markers for Assessing Intra-Tumor Heterogeneity in Cervical Cancer and for the Detection of Circulating Tumor DNA［J］. Int J Mol Sci， 2017，18（10）：2032. doi:10.3390/ijms18102032 doi: 10.3390/ijms18102032
7	SIVARS L， PALSDOTTIR K， CRONA GUTERSTAM Y， et al. The current status of cell-free human papillomavirus DNA as a biomarker in cervical cancer and other HPV-associated tumors： A review［J］. Int J Cancer， 2023，152（11）：2232，2242. doi:10.1002/ijc.34333 doi: 10.1002/ijc.34333
8	BøNLøKKE S， STOUGAARD M， SORENSEN B S， et al. The Diagnostic Value of Circulating Cell-Free HPV DNA in Plasma from Cervical Cancer Patients［J］. Cells， 2022，11（14）：2170. doi:10.3390/cells11142170 doi: 10.3390/cells11142170
9	SIVARS L， HELLMAN K， CRONA GUTERSTAM Y， et al. Circulating cell-free tumor human papillomavirus DNA is a promising biomarker in cervical cancer［J］. Gynecol Oncol， 2022，167（1）：107-114. doi:10.1016/j.ygyno.2022.07.028 doi: 10.1016/j.ygyno.2022.07.028
10	JEANNOT E， LATOUCHE A， BONNEAU C， et al. Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer［J］. Clin Cancer Res， 2021，27（21）：5869-5877. doi:10.1158/1078-0432.ccr-21-0625 doi: 10.1158/1078-0432.ccr-21-0625
11	CABEL L， BONNEAU C， BERNARD-TESSIER A， et al. HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancer［J］. ESMO Open，2021，6（3）：100154. doi:10.1016/j.esmoop.2021.100154 doi: 10.1016/j.esmoop.2021.100154
12	CHEUNG T H， YIM S F， YU M Y， et al. Liquid biopsy of HPV DNA in cervical cancer［J］. J Clin Virol， 2019，114：32-36. doi:10.1016/j.jcv.2019.03.005 doi: 10.1016/j.jcv.2019.03.005
13	辇伟奇，于津浦，袁响林，等. ctDNA高通量测序临床实践专家共识（2022年版）［J］.中国癌症防治杂志， 2022，14（3）：240-252.
14	SPELLMAN P T， GRAY J W. Detecting cancer by monitoring circulating tumor DNA［J］. Nat Med， 2014，20（5）：474-475. doi:10.1038/nm.3564 doi: 10.1038/nm.3564
15	FERRIER S T， TSERING T， SADEGHI N， et al. Blood and saliva-derived ctDNA is a marker of residual disease after treatment and correlates with recurrence in human papillomavirus-associated head and neck cancer［J］. Cancer Med， 2023，12（15）：15777-15787. doi:10.1002/cam4.6191 doi: 10.1002/cam4.6191
16	JEANNOT E， BECETTE V， CAMPITELLI M， et al. Circulating human papillomavirus DNA detected using droplet digital PCR in the serum of patients diagnosed with early stage human papillomavirus-associated invasive carcinoma［J］. J Pathol Clin Res， 2016，2（4）：201-209. doi:10.1002/cjp2.47 doi: 10.1002/cjp2.47
17	BARBANY G， ARTHUR C， LIEDéN A， et al. Cell-free tumour DNA testing for early detection of cancer - a potential future tool［J］. J Intern Med， 2019，286（2）：118-136. doi:10.1111/joim.12897 doi: 10.1111/joim.12897
18	MOSS J， MAGENHEIM J， NEIMAN D， et al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease［J］. Nat Commun， 2018，9（1）：5068. doi:10.1038/s41467-018-07466-6 doi: 10.1038/s41467-018-07466-6
19	ROSTAMI A， LAMBIE M， YU C W， et al. Senescence， Necrosis， and Apoptosis Govern Circulating Cell-free DNA Release Kinetics［J］. Cell Rep， 2020，31（13）：107830. doi:10.1016/j.celrep.2020.107830 doi: 10.1016/j.celrep.2020.107830
20	BROUTET N， JERONIMO J， KUMAR S， et al. Implementation research to accelerate scale-up of national screen and treat strategies towards the elimination of cervical cancer［J］. Prev Med，2022，155：106906. doi:10.1016/j.ypmed.2021.106906 doi: 10.1016/j.ypmed.2021.106906
21	冯同富. 宫颈癌筛查策略的变迁及思考［J］. 实用医学杂志，2022，38（15）：1865-1871. doi:10.3969/j.issn.1006-5725.2022.15.004 doi: 10.3969/j.issn.1006-5725.2022.15.004
22	缪华章，吴云涛，朱颖贤. 2017-2019年广东省农村适龄妇女宫颈癌和乳腺癌筛查结果和成本效果分析［J］. 实用医学杂志， 2023，39（13）：1709-1713. doi:10.3969/j.issn.1006-5725.2023.13.020 doi: 10.3969/j.issn.1006-5725.2023.13.020
23	PHALLEN J， SAUSEN M， ADLEFF V， et al. Direct detection of early-stage cancers using circulating tumor DNA［J］. Sci Transl Med， 2017，9（403）：eaan2415. doi:10.1126/scitranslmed.aan2415 doi: 10.1126/scitranslmed.aan2415
24	GALATI L， COMBES J D， LE CALVEZ-KELM F， et al. Detection of Circulating HPV16 DNA as a Biomarker for Cervical Cancer by a Bead-Based HPV Genotyping Assay［J］. Microbiol Spectr， 2022，10（2）：e0148021. doi:10.1128/spectrum.01480-21 doi: 10.1128/spectrum.01480-21
25	谢玲玲，林荣春，林仲秋. 《2021.2 NCCN外阴鳞癌临床实践指南》解读［J］. 中国实用妇科与产科杂志， 2020，36（12）：1172-1176.
26	RASMUSSEN C L， SAND F L， HOFFMANN FREDERIKSEN M， et al. Does HPV status influence survival after vulvar cancer？［J］. Int J Cancer， 2018，142（6）：1158-1165. doi:10.1002/ijc.31139 doi: 10.1002/ijc.31139
27	SASTRE-GARAU X， DIOP M， MARTIN F， et al. A NGS-based Blood Test For the Diagnosis of Invasive HPV-associated Carcinomas with Extensive Viral Genomic Characterization［J］. Clin Cancer Res， 2021，27（19）：5307-5316. doi:10.1158/1078-0432.ccr-21-0293 doi: 10.1158/1078-0432.ccr-21-0293

研究	入组人数	检测方法	HPV分型	阳性检测限	HPV-ctDNA+（%）	参考文献
B?NL?KKE et al. 2022	晚期（ⅠB3-ⅣA）： 30 早期（ⅠA1-ⅠB2）： 30	ddPCR	HPV16，18	临界值> 3拷贝/mL	63.3% 10.0%	^［8］
SIVARS et al. 2022	晚期d（ⅠB3-ⅣB）： 18 早期e（ⅠB1-ⅡA1）： 15	ddPCR	HPV16，18，45	临界值> 3拷贝/mL	94.4% 26.7%	^［9］
JEANNOT et al. 2021	94	ddPCR	HPV16，18	临界值> 3拷贝/mL	63.0%	^［10］
L Cabel et al. 2021	55	ddPCR	HPV16，18，31，33，35，45，52，58，73	临界值> 3拷贝/mL	69.0%	^［11］
CHEUNG et al. 2019	138	ddPCR	HPV16，18	临界值≥ 20拷贝/mL	61.1%	^［12］

[1]	Jing HU,Xu WANG,Xiaoqin GONG,Rui LING,Tao YOU,Chunhua DAI,Ye TIAN,Fei. CHEN. Analysis of dosimetric parameters of acute radiation enteritis in cervical cancer patients treated with concurrent chemoradiotherapy [J]. The Journal of Practical Medicine, 2024, 40(5): 672-676.
[2]	Ping LI,Tuo TANG,Aixue ZHENG,Luping ZHANG,Tao WANG,Xian HONG,Zhihui DENG. Generation of MCM2 gene inducible knockout cervical cancer HeLa cells and its effect on DNA replication [J]. The Journal of Practical Medicine, 2024, 40(2): 133-139.
[3]	Shenglong YUAN,Huanhuan HU,Zhen GONG. Efficacy of the ACS NSQIP surgical risk calculator in open radical hysterectomy [J]. The Journal of Practical Medicine, 2024, 40(2): 140-145.
[4]	Min WANG,Dan MU,Dejun KONG,Li YANG,Lu YE,Dan HE. HPV16 E6 regulates miR-23a expression and promotes invasion and migration of cervical cancer cells [J]. The Journal of Practical Medicine, 2024, 40(2): 146-152.
[5]	Fei CHEN,Xiaoqin GONG,Yunpeng YU,Tao YOU,Xu WANG,Chunhua DAI,Jing HU. Feasibility of automatic segmentation of CTV and OARs in postoperative radiotherapy for cervical cancer using AccuLearning [J]. The Journal of Practical Medicine, 2024, 40(2): 153-157.
[6]	Yongzhen ZHANG,Shanshan WANG,Hailing ZHAO,Liwei. XU. Levels and clinical significance of serum miR-651 and miR-630 in patients with cervical cancer [J]. The Journal of Practical Medicine, 2024, 40(2): 158-162.
[7]	Pixi WEI,Yu DENG,Cailing ZHAO,Liu XU,Min ZHANG. The expression of WDR5 in cervical cancer tissue and its relationship with clinical and pathological characteristics of patients [J]. The Journal of Practical Medicine, 2024, 40(2): 169-173.
[8]	Qingwei ZHANG,Rutie. YIN. Hotspots and advances on diagnosis and treatment for cervical cancer [J]. The Journal of Practical Medicine, 2024, 40(17): 2357-2362.
[9]	Yaling LI,Gang NIU,Wei. WANG. Impact of high⁃risk HPV infections on pregnancy outcomes and vaginal microenvironment [J]. The Journal of Practical Medicine, 2024, 40(15): 2138-2141.
[10]	ZHONG Hua, ZENG Meiqing, ZHOU Yuting, HE Shunqing, LU Binghui.. Transfection of human cervical cancer cell HeLa by ultrasound microbubble contrast agent carrying pcD⁃ NA⁃STC1 [J]. The Journal of Practical Medicine, 2023, 39(8): 936-943.
[11]	LU Yanyue, ZHAO Xinxin, LIU Liyan, WANG Kai, YE Jingwen, LIU Lingyun, WANG Baojin.. Effect and mechanism of endogenous aromatic ligand ITE on the biological behavior of cervical cancer cells [J]. The Journal of Practical Medicine, 2023, 39(6): 679-687.
[12]	Huaming ZHANG,Wanshan HE,Yun HAN,Guanqiao CHEN,Bin CHEN,Zhifu WEI,Hengying WU,Bin. WEN. Screening of gene differential expression of adenosine deaminase RNA specific 1 in cervical cancer cells based on transcriptome sequencing technology [J]. The Journal of Practical Medicine, 2023, 39(24): 3169-3174.
[13]	Guang YANG,Danfeng ZHANG,Xiaona FENG,Yan. ZHANG. Expression of programmed cell death protein 5 in cervical cancer and its relationship with lymph node metastasis [J]. The Journal of Practical Medicine, 2023, 39(24): 3210-3213.
[14]	Ping YIN,Hanzi XU,Chenjing. ZHU. Application of ctDNA in gynecological malignant cancer [J]. The Journal of Practical Medicine, 2023, 39(17): 2153-2158.
[15]	WEN Lifang , DING Jie. . Study on the relationship between the expression of SLIT3 and SPARCL1 protein and the recurrence after radical operation in cervical cancer [J]. The Journal of Practical Medicine, 2023, 39(15): 1907-1912.

Application and prospects of ctDNA detection in HPV associated cervical cancer

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 27

Related Articles 15

Recommended Articles

Metrics

Comments